Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors
Status:
Completed
Trial end date:
2020-07-16
Target enrollment:
Participant gender:
Summary
The overall goal is to study the feasibility of darunavir/ritonavir (DRV/r) monotherapy as
treatment simplification (switch) in pretreated pregnant women, associated with neonatal
prophylaxis with nevirapine, constituting a PMTCT strategy without any Nucleoside Reverse
Transcriptase Inhibitor (NRTIs) .
Phase:
Phase 2
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)